Notably, treatment with PRT543 resulted in downregulation of MYB, MYC (Fig. 3F and G) and a subset of other ACC-associated genes such as transcription factors (EN1, FOXM1, RUNX1, SOX8), extracellular matrix components (ITGB1, VCAN), mitogenic regulators of cell-cycle progression (POLD1, ITGB1, IGF2), pro-survival oncogenes (KIT and AXL), and apoptosis suppressor (BCL2) (Fig. 3H), supporting the multifaceted role of PRMT5 in regulating ACC cancerogenesis [40]. This evidence concerns the gene POLD1 and adrenal cortex carcinoma.